Bottmedical generates growing revenues

Oral health is the gateway to body health. However, our daily oral hygiene habits have not changed for nearly a century. Bottmedical made it its mission to innovate current oral/dental care standards by implementing invisible braces in daily oral care. Co-founded in 2019 from the University of Basel by Tino Töpper and Bekim Osmani, Bottmedical specialises in cellulose-based dental braces which allow for teeth alignment, retention of their position, and protection against grinding.

Novel to these dental appliances is the company’s patent-protected biopolymer material, which allows for embedding natural antibacterial agents resulting in an improved smell/taste and antibacterial efficacy related to the most common oral diseases. As the material system is based on natural plasticizers and antibacterial substances the Bottmedical blocks the release of toxic substances to the body, says Tino Töpper.

After successfully piloting their Naturaligner therapy, Bottmedical is introducing invisible dental braces as a multifunctional tool – “CINNA” - an antibacterial brace that fights caries bacteria while wearing it. It is envisioned to prevent plaque formation and inflammation of gums for millions of caries & periodontitis-risk patients and improve people’s oral hygiene worldwide.

According to the startup, CINNA is the world’s only invisible brace that can keep users’ gums and teeth healthy while preventing the teeth from shifting back after the aligner therapy. They also protect the teeth against tooth abrasion caused by teeth grinding. The product’s name CINNA originates from Cinnamaldehyde, the main ingredient responsible for the antibacterial effect. Launched in July 2022, the CE-certified product is already offered in selected clinics in Switzerland and Germany.

Clinics in the DACH region rely on Bottmedical
Bottmedical builds on an international network of clinicians who have already applied their first product, Naturaligner as clear aligner therapy, which obtained the CE certification in July 2021. The product is now available worldwide including in Switzerland, Germany, Japan, Oman, and Hong Kong. In addition to its continued geographical expansion, Bottmedical is generating growing revenues which, according to Tino Töpper, have organically doubled since last year.

Focusing on boosting revenues for both products, the Bottmedical team, which comprises eight people today, has shifted from being an R&D-focused tech start-up to including sales as part of its strategy.“Our mission is to bring our products to more patients and clinics worldwide during the next growth phase,” said Tino Töpper.

The startup plans to boost its commercial activities in new strategic markets over the coming years and to strengthen their medical claims with clinical trials on the prevention of periodontitis and peri-implantitis. To achieve these goals, Bottmedical is launching a CHF 4 million series B financing round. The funds from the round will also enable the startup to file for approval from the US Food and Drug Administration. This will lay a foundation for expanding into the American market. According to Tino, there is a vast market potential for Naturaligner and CINNA in the US.

(RAN)